Condition
Mature B-Cell Lymphoma
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07525817Not Yet RecruitingPrimary
A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma
NCT01046825Phase 2Active Not RecruitingPrimary
Mature B-Cell Lymphoma And Leukemia Study III
NCT07113496Phase 1Not Yet Recruiting
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT04088422RecruitingPrimary
Cell Free DNA in Mature B-cell Lymphoma
Showing all 4 trials